Investigators at the Northwestern University Feinberg School of Medicine are currently enrolling participants for a clinical trial (ClinicalTrials.gov Identifier: NCT00821132), that aims to identify genes that increase risk for sporadic Amyotrophic Lateral Sclerosis (ALS) or cause inherited ALS. The study, entitled “Identification of Genes Causing Familial ALS or Increasing Risk…
BioMotiv is a drug advancement accelerator associated with The Harrington Project, the University of California San Francisco (UCSF), and University of Washington, Seattle working on breakthrough discoveries and new therapeutics that have the potential to address unmet clinical needs. Recently, the accelerator announced the creation of a platform company, OptiKira, that will…
The first app for amyotrophic lateral sclerosis (ALS) patients who have begun to lose their speaking abilities was recently launched by UK company Therapy Box. The app was designed to substitute standard text-to-speech synthesis with a synthesizer based on the patient’s own voice. The Predictable 4 app has entered the ModelTalker program, at a…
Dr. Nancy Bonini A recent editorial published in the journal Neurology highlights the existing scope of clinical knowledge concerning genetic susceptibility that makes individuals prone to developing amyotrophic lateral sclerosis (ALS). The editorial content was based on a thorough…
A research team from the University of Wisconsin-Madison Waisman Center led by Su Chun Zhang, established a simple model in mice to investigate the role of human astrocytes in neurologic diseases such as Amyotrophic Lateral Sclerosis (ALS), Rett Syndrome and Huntington’s disease. The study entitled…
Dual platform regenerative medicine company, Neuralstem, Inc., is wrapping up its participation in the 17th Annual BIO CEO & Investor Conference taking place February 9 to the 10th at the Waldorf Astoria in New York. President and CEO, Richard Garr, was invited to present…
Biopharmaceutical company Genervon recently reported observing improvements in a 46-year-old-man with advanced amyotrophic lateral sclerosis (ALS) taking the Company’s drug candidate GM604. The patient showed increased speech, swallowing and suction capabilities after a 12-week treatment. The drug, which has yet to be approved by the…
A recent study, titled, “Early detection of structural abnormalities and cytoplasmic accumulation of TDP-43 in tissue-engineered skins derived from ALS patients,” published in the journal, Acta Neuropathologica Communications, details the creation of a novel tissue-engineered skin model for amyotrophic lateral sclerosis (ALS). ALS is a progressive…
In a new study, researchers found the mechanism behind the degeneration of upper motor neurons in the brain, which current evidence has strongly linked to disease progression in patients suffering from amyotrophic lateral sclerosis (ALS). The findings were published in the journal Cerebral Cortex…
A research group at Duke University accomplished a pioneering feat in laboratory synthesis. They were able to grow the world’s first human muscle that is able to contract and respond to external stimuli, just like normal human tissue, and to respond to biochemical signals and pharmaceuticals. This new discovery can…
